Eagle Pharmaceuticals Inc. (EGRX)

55.24
NASDAQ : Health Technology
Prev Close 55.24
Day Low/High 0.00 / 0.00
52 Wk Low/High 45.05 / 97.15
Avg Volume 236.80K
Exchange NASDAQ
Shares Outstanding 14.92M
Market Cap 819.79M
EPS 3.40
P/E Ratio 16.80
Div & Yield N.A. (N.A)

Latest News

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2017.

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Year End 2017 Financial Results On February 26, 2018

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Year End 2017 Financial Results On February 26, 2018

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced that the Company will release its 2017 fourth quarter and full year financial results on Monday, February 26, 2018, before the market...

EGRX Crosses Above Key Moving Average Level

EGRX Crosses Above Key Moving Average Level

In trading on Thursday, shares of Eagle Pharmaceuticals, Inc. crossed above their 200 day moving average of $62.84, changing hands as high as $63.52 per share.

Eagle Pharmaceuticals, Inc. To Present At 2018 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 2018 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2018 RBC Capital Markets Global...

Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent For RYANODEX

Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent For RYANODEX

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the Company has been issued a new patent related to its RYANODEX ® product (dantrolene sodium for injectable suspension) by the...

Eagle Pharmaceuticals Reaches Analyst Target Price

Eagle Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $62.33, changing hands for $62.56/share.

Eagle Pharmaceuticals, Inc. To Present At 36th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 36th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 36th Annual J.

EGRX: Insiders vs. Shorts

EGRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 11/30/2017 settlement date, and Eagle Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 18.70 "days to cover" versus the median component at 5.11.

PayPal, Skyworks Solutions, Cisco Systems: 'Mad Money' Lightning Round

PayPal, Skyworks Solutions, Cisco Systems: 'Mad Money' Lightning Round

Jim Cramer makes a call on PayPal, Skyworks Solutions, Cisco Systems, Frontier Communications and more.

Get Your Game Plan Ready: Cramer's 'Mad Money' Recap (Friday 12/15/17)

Get Your Game Plan Ready: Cramer's 'Mad Money' Recap (Friday 12/15/17)

Earnings are still in charge of this bull, says Jim Cramer. You can't keep good market down.

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that it has begun dosing subjects in its pivotal study for the Company's fulvestrant formulation intended as a monotherapy treatment of...

Eagle Pharmaceuticals, Inc. To Present At 29th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 29th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 29th Annual Piper Jaffray...

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three- and nine-months ended September 30, 2017.

Eagle Pharmaceuticals, Inc. To Present At Jefferies 2017 London Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At Jefferies 2017 London Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conferences as follows: ...

Eagle Pharmaceuticals, Inc. To Discuss Third Quarter 2017 Financial Results On November 8, 2017

Eagle Pharmaceuticals, Inc. To Discuss Third Quarter 2017 Financial Results On November 8, 2017

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced that the Company will release its 2017 third quarter financial results on Wednesday, November 8, 2017, before the market opens.

Eagle Pharmaceuticals Receives Tentative FDA Approval For PEMFEXY (Pemetrexed Injection) Ready-to-Dilute

Eagle Pharmaceuticals Receives Tentative FDA Approval For PEMFEXY (Pemetrexed Injection) Ready-to-Dilute

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the United States Food and Drug Administration ("FDA") has granted tentative approval for the Company's PEMFEXY™, a pemetrexed...

Eagle Pharmaceuticals Announces New Patent For RYANODEX

Eagle Pharmaceuticals Announces New Patent For RYANODEX

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the Company has been issued a new patent related to its RYANODEX ® formulation (dantrolene sodium) by the United States Patent...

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.

Eagle Pharmaceuticals Licenses Japanese Rights For Bendamustine Hydrochloride Ready-to-dilute And Rapid Infusion Injection Products To SymBio Pharmaceuticals Limited

Eagle Pharmaceuticals Licenses Japanese Rights For Bendamustine Hydrochloride Ready-to-dilute And Rapid Infusion Injection Products To SymBio Pharmaceuticals Limited

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") and SymBio Pharmaceuticals Limited ("SymBio") (Tokyo Stock Exchange/JASDAQ 4582) today announced that the Company has licensed to SymBio rights under...

Short Interest Increases 13% For EGRX

Short Interest Increases 13% For EGRX

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 379,650 share increase in total short interest for Eagle Pharmaceuticals, Inc. , to 3,324,054, an increase of 12.89% since 08/15/2017.

Eagle Pharmaceuticals, Inc. To Present At September Investor Conferences

Eagle Pharmaceuticals, Inc. To Present At September Investor Conferences

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two investor conferences in...

Eagle Pharmaceuticals Announces Positive Results Of Study Conducted To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure

Eagle Pharmaceuticals Announces Positive Results Of Study Conducted To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced positive results of an initial study in over 50 rodents to evaluate the neuroprotective effects of RYANODEX ® (dantrolene sodium) in...

Oversold Small-Cap Biotech Names

Oversold Small-Cap Biotech Names

I am working incrementally into some small stocks with great long-term value.

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three and six months ended June 30, 2017.

New 52-Week Low Could Prompt More Insider Buying At EGRX

New 52-Week Low Could Prompt More Insider Buying At EGRX

In trading on Monday, shares of Eagle Pharmaceuticals, Inc. touched a new 52-week low of $46.05/share.

Eagle Pharmaceuticals, Inc. To Discuss Second Quarter 2017 Financial Results On August 9, 2017

Eagle Pharmaceuticals, Inc. To Discuss Second Quarter 2017 Financial Results On August 9, 2017

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) announced today that the Company will release its 2017 second quarter financial results on Wednesday, August 9, 2017, before the market opens.

Oversold Conditions For Eagle Pharmaceuticals (EGRX)

Oversold Conditions For Eagle Pharmaceuticals (EGRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: C+ (Hold)